Analisis Implikasi Perubahan Kurikulum Terhadap Pembelajaran PPKn Pada Sekolah Jenjang SD

In writing scientific papers based on literature studies, it is hoped that it will be able to overcome confusion over the problem of curriculum policies which often change, which are policies from the government under the pretext of the times and technology so that the curriculum must also always experience changes. The curriculum has a dynamic nature and continues to be developed or adapted according to the context and needs of students to build competencies or abilities according to the present and the future. What is needed in the educational process in curriculum development is that it is hoped that all educational academics will be able to collaborate with the community to organize socialization for all components of society, namely the role of parents, communities and schools must place needs, opinions, experiences, learning outcomes and the interests of students as curriculum development because The curriculum is designed for the needs of learners. In the subjects there were also changes in terms of the naming of the subjects which were originally Pancasila Education and Citizenship changed their names to Pancasila Education, in the contents of the content of the lesson values also added the profile of Pancasila students as strengthening character values, implementing Pancasila personality as an example in the behavior of daily life - day. By changing the curriculum, of course, it can further improve the understanding of learning material, create a new view of learning programs that should be carried out, be more flexible, concise and efficient and be able to answer challenges in the world of education in the current era of digital technology development. So each curriculum in its implementation requires evaluation every year in order to determine the level of success of the learning process of students

Outcomes after perioperative SARS-CoV-2 infection in patients with proximal femoral fractures: an international cohort study

Objectives Studies have demonstrated high rates of mortality in people with proximal femoral fracture and SARS-CoV-2, but there is limited published data on the factors that influence mortality for clinicians to make informed treatment decisions. This study aims to report the 30-day mortality associated with perioperative infection of patients undergoing surgery for proximal femoral fractures and to examine the factors that influence mortality in a multivariate analysis. Setting Prospective, international, multicentre, observational cohort study. Participants Patients undergoing any operation for a proximal femoral fracture from 1 February to 30 April 2020 and with perioperative SARS-CoV-2 infection (either 7 days prior or 30-day postoperative). Primary outcome 30-day mortality. Multivariate modelling was performed to identify factors associated with 30-day mortality. Results This study reports included 1063 patients from 174 hospitals in 19 countries. Overall 30-day mortality was 29.4% (313/1063). In an adjusted model, 30-day mortality was associated with male gender (OR 2.29, 95% CI 1.68 to 3.13, p80 years (OR 1.60, 95% CI 1.1 to 2.31, p=0.013), preoperative diagnosis of dementia (OR 1.57, 95% CI 1.15 to 2.16, p=0.005), kidney disease (OR 1.73, 95% CI 1.18 to 2.55, p=0.005) and congestive heart failure (OR 1.62, 95% CI 1.06 to 2.48, p=0.025). Mortality at 30 days was lower in patients with a preoperative diagnosis of SARS-CoV-2 (OR 0.6, 95% CI 0.6 (0.42 to 0.85), p=0.004). There was no difference in mortality in patients with an increase to delay in surgery (p=0.220) or type of anaesthetic given (p=0.787). Conclusions Patients undergoing surgery for a proximal femoral fracture with a perioperative infection of SARS-CoV-2 have a high rate of mortality. This study would support the need for providing these patients with individualised medical and anaesthetic care, including medical optimisation before theatre. Careful preoperative counselling is needed for those with a proximal femoral fracture and SARS-CoV-2, especially those in the highest risk groups. Trial registration number NCT0432364